Status:
UNKNOWN
Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial
Lead Sponsor:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Conditions:
Prostate Cancer
Eligibility:
MALE
18-80 years
Brief Summary
The Immune compleX Predictive Index (iXip) is a predictive tool for prostate cancer (PCa) diagnosis that integrates PSA, PSA-IgM, prostate volume and age of the patient. An algorithm processes these p...
Detailed Description
Since the 90s, serum PSA has become the cornerstone of diagnosis of PCa, However, due to its proven poor specificity, the actual role of PSA testing has been largely debated, especially if used during...
Eligibility Criteria
Inclusion
- Inclusion Criteria are:
- histologically proven prostate cancer,
- patients scheduled for radical prostatectomy
- paziente able to provide consent
- age \> 18 years or \< 80 years
- Exclusion criteria are:
- neiadjuvant hormone therapy
- salvage radical prostatectomy
- concomitant solid or hematological tumors,
- autoimmune disorders
- or immunosuppressive therapies,
- acute bacterial or viral infections.
Exclusion
Key Trial Info
Start Date :
February 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03413007
Start Date
February 9 2018
End Date
December 1 2018
Last Update
July 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST Spedali Civili of Brescia
Brescia, BS, Italy, 25123